1. Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients.
- Author
-
Coelho, Luís, Falcão, Fatima, Póvoa, Pedro, Viegas, Erica, Martins, Antonio Pais, Carmo, Eduarda, Fonseca, Candida, Campos, Luis, Mansinho, Kamal, Carmo, Inês, Soares, Joana, Solano, Mariana, Mendes, Dina, Miranda, Ana Cláudia, Carvalho, Antonio, Mirco, Ana, Farinha, Helena, Aldir, Isabel, and Correia, José
- Subjects
SARS-CoV-2 ,COVID-19 ,COVID-19 treatment ,HOSPITAL patients ,ADULT respiratory distress syndrome - Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7–12.8; 14.9–17.1; p =.016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF